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COMPARISON OF PHARMACOECONOMIC (PE) EVALUATIONS FOR DRUGS FOR RARE DISEASES 
(DRDS) EVALUATED BY CADTH AND NICE. 
Gosain S1, Bullement A2, Kirby J1, Ralph L2, Lilley C2, Lawrence D1 
1PDCI Market Access, Ottawa, ON, Canada, 2BresMed Health Solutions, Sheffield, UK 
 
OBJECTIVES: The processes by which DRDs are evaluated varies across health technology 
assessment (HTA) agencies. The objective of this analysis was to determine trends in how the 
Canadian Agency for Drugs and Technologies (CADTH) and the National Institute for Health and Care 
Excellence (NICE) evaluated DRDs, including factors influencing the recommendations issued, to 
support decision-making and inform best PE practices for DRDs. 
METHODS: CADTH DRD recommendations issued between March 2016 and June 2018 were 
reviewed, and equivalent NICE recommendations were identified. DRDs were excluded where a 
recommendation was not issued by both agencies. The recommendation(s) made, incremental cost 
effectiveness ratios (ICERs), and PE methods used within the submissions were then extracted and 
compared to identify key trends in how the evidence was appraised. 
RESULTS: Nine DRD recommendations were issued by CADTH and NICE. The mean time from 
submission to recommendation was approximately 6.3 months for CADTH, and 7.8 months for NICE. 
NICE applied three different processes for the evaluation of the identified DRDs: highly specialized 
technology appraisal (n=4), single technology appraisal (n=4), and multiple technology appraisal 
(n=1). No differential processes were applied for DRDs by CADTH. Despite this, final 
recommendations were similar (positive: n=7 (NICE), n=8 (CADTH); ongoing/negative: n=2 (NICE), 
n=1 (CADTH)). Similar PE methods were used in the manufacturer-submitted PE evaluations. In all 
cases the HTA reanalysis ICERs were higher than the manufacturer-submitted ICERs, with the 
magnitude of difference being greater in the CADTH submissions. 
CONCLUSIONS: While different processes are used by NICE and CADTH, and the reasons for the 
recommendations vary, the methods used, and final recommendations made were broadly 
consistent. Differences in the HTA re-analysis ICERs when compared with the manufacturers 
submission are indicative of the challenges associated with conducting economic evaluations for 
DRDs. 
